Fumapharm (Royalty interest in BG-12 and Fumaderm) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Fumapharm (Royalty interest in BG-12 and Fumaderm) General Information

Description

A portfolio of royalty interests in therapeutic medicines. The portfolio comprises of BG-12, an oral therapeutic medicine for the treatment of relapsing-remitting multiple sclerosis and Fumaderm, a therapeutic medicine for the treatment of moderate to severe plaque psoriasis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Haldenstr. 24a
  • 6006 Lucerne
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Fumapharm (Royalty interest in BG-12 and Fumaderm) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fumapharm (Royalty interest in BG-12 and Fumaderm)‘s full profile, request access.

Request a free trial

Fumapharm (Royalty interest in BG-12 and Fumaderm) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Fumapharm (Royalty interest in BG-12 and Fumaderm)‘s full profile, request access.

Request a free trial